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Pharmacotherapies for drug abuse treatment and rehabilitation are generally limited to drug receptor agonists and antagonists (Kreek et al., 2002) . Although monoclonal antibodies (mAbs 2 ) and antigen binding fragments (Fabs) have been used clinically to reverse toxicity resulting from digoxin and snake venom for some time (Sullivan, 1986) , their usefulness for drug abuse treatment is still at the stage of preclinical investigation. In addition to treating drug overdose, investigators are exploring passive immunization as a mechanism to reduce or prevent drug effects and/or toxicity (e.g., Malin et al., 2001; Hardin et al., 2002) . Pretreatment with a highly specific anti-drug mAb could potentially block or suppress the effects of the drug, which could aid the patient in discontinuing use of the drug. In addition, mAb pretreatment could prevent or reduce toxicity associated with excessive drug exposure.
There are other potential advantages of mAb treatment over conventional small molecule receptor agonists and antagonists. First, mAbs target the drug rather than the receptor; therefore they should have no intrinsic effect on receptor activity. Second, mAbs have a relatively small volume of distribution (Vd) and do not readily penetrate tissues (Bazin-Redureau et al., 1997) . Through high-affinity binding, they are thus able to reverse toxicity by altering disposition of the drug and preventing the drug from reaching its site of action. Finally, mAbs have a relatively long half-life (ϳ21 days in humans; Knapp and Colburn, 1990) , which would allow long intervals between treatments and thus improve compliance of patients in drug abuse rehabilitation programs.
Previous studies, from our laboratory and others, have examined the use of mAbs in overdose treatment scenarios (i.e., administration of mAb after a high dose of drug). Our laboratory has shown that administration of anti-drug mAb or Fab reverses drug-induced behavioral effects and alters drug pharmacokinetics in rat models of (ϩ)-methamphetamine [(ϩ)-METH] and phencyclidine (PCP) overdose (e.g., Proksch et al., 2000; Byrnes-Blake et al., 2003) . The mAb "pretreatment" or "protection" model for reduction or prevention of drug effects has not been examined as thoroughly. We have shown that pretreatment with an anti-PCP mAb will substantially reduce behavioral effects resulting from repeated PCP chal- period for the 1 mg/kg (ϩ)-METH dose used in this study (i.e., ϳ2.5 h of increased locomotor activity; Rivière et al., 1999; Byrnes-Blake et al., 2003) . For the early time points (1 and 5 min), the rats were anesthetized with ethyl ether before (ϩ)-METH injection so that blood and brain tissue could be collected rapidly at the appropriate time. At the later time points, rats were anesthetized with ethyl ether 5 min before the desired time of sacrifice. Ethyl ether was used for maintenance of hemodynamic stability. After laparotomy, blood was collected from the inferior vena cava and the rats were immediately decapitated. The brain, right testis, right liver lobe, kidney, and spleen were harvested, rinsed with saline, weighed, and frozen in liquid nitrogen within 3 min. Whole blood hematocrits were determined for each rat for use in pharmacokinetic calculations. The blood was allowed to clot at room temperature for 1 h and then centrifuged at 230g for 10 min to obtain serum. All samples were stored at -80°C until analysis. Analysis of Drug Concentrations in Serum and Tissue. Tissues were homogenized in 5 volumes of ice-cold water. (ϩ)-METH and (ϩ)-AMP were extracted from serum and homogenized brain, testis, liver, and spleen tissue samples using a solid-phase extraction procedure as described by ByrnesBlake et al. (2003) . For kidney samples, a liquid-liquid extraction procedure was used. This procedure consisted of mixing 200 l of kidney homogenate with 200 l of 1 M NaCO 3 . A 70:30 (v/v) hexane/ethyl acetate mixture (3.2 ml) was then added. The samples were then incubated on a rotary device for 15 min and centrifuged at 700g, and the organic layer was transferred to a clean siliconized test tube. The solvent extracts were taken to dryness under a nitrogen stream and resuspended in 120 l of 10% acetonitrile/90% H 2 O. The extraction recoveries for serum and brain were 84 to 96% and were 72 to 84% for testis, 68 to 92% for liver, 64 to 88% for spleen, and 68 to 80% for kidney. Recoveries were independent of concentration. In addition, the denaturation and precipitation of protein with guanidine and ZnSO 4 , respectively (ByrnesBlake et al., 2003) , removed the effect of the mAb on (ϩ)-METH and (ϩ)-AMP recovery. (ϩ)-METH and (ϩ)-AMP dpm recovered were determined by liquid scintillation spectrometry following high-pressure liquid chromatography separation on a Waters Symmetry Shield RP18 column (3.5-m, 4.5 ϫ 75 mm) using an isocratic 10% acetonitrile/90% H 2 O mobile phase as previously described (Byrnes-Blake et al., 2003) . The serum and tissue drug concentrations were determined by converting the dpm of (ϩ)-METH or (ϩ)-AMP to milligrams, using the ratio of unlabeled methamphetamine to radiolabeled methamphetamine tracer. This value is then corrected for percentage recovery and dilution factor. Tissue drug concentrations were then corrected for blood content in the tissues as described by . Briefly, when no monoclonal antibody was present, the whole-blood drug concentration was assumed to be equal to the serum drug concentration, since methamphetamine and amphetamine distribute about equally in red blood cells and serum (Rivière et al., 2000) . When the monoclonal antibody was present, the drug was confined mostly to the serum (rather than in the red blood cells) through high-affinity monoclonal antibody binding. The methamphetamine or amphetamine concentration in whole blood for this calculation was determined by multiplying the serum drug concentration by 1 Ϫ hematocrit for each animal .
(؉)-METH Serum Protein Binding. (ϩ)-METH serum protein binding in the control and mAb-treated rats was determined by equilibrium dialysis. Aliquots of serum samples (700 l) from the pharmacokinetic studies were placed in one side of a 2-ml Teflon dialysis cell, divided with a 3500 molecular weight cut-off dialysis membrane. In the other side, 700 l of 0.13 M sodium phosphate buffer (pH 7.4) was added. The dialysis cells were incubated with constant rotation in a 37°C water bath for 5 h. After incubation, the serum and buffer were removed from each side of the dialysis chamber. The serum was then extracted as previously described (Byrnes-Blake et al., 2003) and analyzed by high-pressure liquid chromatography and liquid scintillation spectrometry as described above. The fraction of unbound (ϩ)-METH was calculated by dividing the unbound (ϩ)-METH dpm in the buffer side by the total (ϩ)-METH dpm in the serum side. (ϩ)-AMP protein binding could not be determined due to technical difficulties.
Pharmacokinetic Analysis. Pharmacokinetic analyses of (ϩ)-METH and (ϩ)-AMP concentration-time data were conducted by means of both modeldependent and model-independent methods using WinNonlin software (Pharsight, Mountain View, CA). For model-dependent pharmacokinetic analysis, bi-and tri-exponential curves with a first-order input function were fit to the average concentration-time data sets using a 1/y and 1/y 2 (where y is the predicted concentration) weighting function. The best-fit line was selected after visual inspection of the fit of each curve to the data, analysis of the residuals, and assessment of precision with coefficients of variation for each parameter. Because drug bound to mAb takes on the pharmacokinetic profile of the mAb (Proksch et al., 2000) , and the elimination half-life (t 1/2Z ) of mAb in rats is ϳ8 days (Bazin-Redureau et al., 1997), some tissue pharmacokinetic parameters for (ϩ)-METH and (ϩ)-AMP could not accurately be determined due to the limited time period of sampling. We would have needed to collect samples for 4 to 7t 1/2Z (e.g., 16 -28 days) to accurately estimate t 1/2Z . Therefore, to make comparisons between control and mAb-treated animals, area under the tissue concentration versus time curve (AUC) was determined from t ϭ 0 [time of (ϩ)-METH administration] to 4.5 h (the last measured time point, AUC 0 4.5 h ). Statistical Analysis. To assess mAb-induced changes in (ϩ)-METH and (ϩ)-AMP serum or tissue concentrations at each time point, a Student's two-tailed t test was used. All t tests were conducted with SigmaStat V1.0 software (SPSS Inc., Chicago, IL), and a significance level of p Ͻ 0.05 was used for these tests. The Bailer method was used for calculating AUC 0 4.5 h and its standard error, based on the experimental data (Nedelman et al., 1995) . Additionally, the t test prescribed by the method was conducted to compare control and mAb groups for each of the 12 combinations of tissue and drug. Since 12 tests were done, a Bonferroni significance was declared if the p value was less than 0.002 (0.05/2*12).
Results

Effect of Anti-(؉)-METH mAb on Serum Pharmacokinetics.
The control (no mAb treatment) (ϩ)-METH concentration-time data shown in Fig. 1 have been previously published (Byrnes-Blake et al., 2003) ; however, the current mAb6H4 studies were carried out in parallel with the control studies. Administration of the anti-(ϩ)-METH mAb, 17 h before (ϩ)-METH administration, led to significantly higher total concentrations of (ϩ)-METH in the serum compared with controls throughout the entire 4.5-h experiment (Fig. 1,  upper panel) . A small but statistically significant increase in serum (ϩ)-AMP serum concentration at the 2-, 3-, and 4.5-h time points was also observed (Fig. 1, lower panel) . The t 1/2Z values of (ϩ)-METH and (ϩ)-AMP in serum and tissue of control rats were consistent with our previous studies (data not shown; Rivière et al., 2000) . The t 1/2Z of (ϩ)-METH and (ϩ)-AMP in the mAb-treated group could not be accurately estimated due to an insufficient sampling time (as discussed under Materials and Methods). However, even with a limited sampling period, it is clear that the t 1/2Z of (ϩ)-METH is substantially increased in the mAb-treated group. The value for the serum (ϩ)-METH AUC 0 4.5 h was significantly increased (Ͼ6600%) in the presence of mAb, whereas there was no change in serum (ϩ)-AMP AUC 0 4.5 h when compared with controls (Table 1) . Serum protein binding estimates revealed that pretreatment with mAb6H4 led to significantly increased serum protein binding compared with controls (Fig. 2, upper panel) . In the controls, (ϩ)-METH binding remained constant and very low over time (ϳ1-10%). In the mAb-treated rats, (ϩ)-METH binding increased from 88% to 99% bound over the first three time points, and then remained constant at high levels. Free concentrations of (ϩ)-METH (determined by multiplying average fraction unbound by total serum concentrations) in mAb-treated rats were not dramatically different from those in control rats, with significant decreases only at the 15-and 38-min time points (Fig. 2, lower panel) . Although we did not have a complete dataset for the protein binding, the free (ϩ)-METH AUC 0 4.5 h in mAb-treated rats was estimated with the assumption that the percentage bound at 270 min was the same as 180 min. With this assumption, the free (ϩ)-METH AUC 0 4.5 h was estimated to be 241 ng ⅐ hr/ml, which was not significantly different from the control (ϩ)-METH AUC 0 4.5 h . It is important to note that the serum protein binding data were derived under equilibrium conditions in vitro and may not accurately reflect serum protein binding in vivo. Thus, the bound and unbound serum (ϩ)-METH concentrations are only an estimation of in vivo values.
Effect of Anti-(؉)-METH mAb on Tissue (؉)-METH and (؉)-AMP Disposition. The significant increase in (ϩ)-METH serum concentrations was accompanied by a significant decrease in (ϩ)-METH brain concentrations (Fig. 3, upper panel) . The mAb also led to significantly lower (ϩ)-AMP concentrations in the brain compared with controls (Fig. 3, lower panel) . In addition, the value for the brain (ϩ)-METH and (ϩ)-AMP AUC 0 4.5 h was significantly decreased in mAb-treated rats compared with controls (Table 1) . Table 1 and Fig. 4 summarize the pharmacokinetics of (ϩ)-METH and (ϩ)-AMP in selected tissues from control and mAb-treated rats. The serum and tissue (ϩ)-METH and (ϩ)-AMP data from control rats are in good agreement with previous studies from our laboratory (Rivière et al., 2000) . Like the serum, in the presence of mAb, liver and testis (ϩ)-METH t 1/2Z appeared to increase substantially but could not be accurately estimated due to an insufficient sampling time. Similar to serum, liver and testis (ϩ)-METH AUC 0 4.5 h values were increased in mAb-treated rats; however, in testis the increase was not significant. The kidney data were similar to those of the brain; that is, 4.5 h in testis and spleen of mAb-treated rats was not significantly different from the control values; however, the (ϩ)-AMP AUC 0 4.5 h for the spleen was significantly decreased.
Due to the differential effects of the mAbs on (ϩ)-METH and (ϩ)-AMP in serum, testis, and liver, there were major changes in the molar ratio of AUC AMP to AUC METH (Table 2 ). In tissues from mAb-treated rats in which (ϩ)-METH and (ϩ)-AMP t 1/2Z did not change, there was no effect on the ratio of (ϩ)-METH to (ϩ)-AMP compared with controls. The tissue-to-serum ratio of (ϩ)-METH and (ϩ)-AMP AUC 0 4.5 h was dramatically altered in all tissues from rats pretreated with mAb. In control rats, the ratio of tissue (ϩ)-METH to serum total (ϩ)-METH AUC 0 4.5 h was always greater than 1; however, in anti-(ϩ)-METH mAb-pretreated rats, the ratio was always substantially less than 1. When the estimated free serum (ϩ)-METH AUC 0 4.5 h was used in the tissue-to-serum ratio calculation (values in parentheses in Table 2 ), the ratio was dramatically decreased in brain and kidney, relatively unchanged in testis and spleen, and increased in liver. The (ϩ)-AMP serum-to-tissue ratio decreased by about 50 to 60% in mAb-pretreated rats compared with controls (Table 2) .
Discussion
This study examined the effects of anti-(ϩ)-METH mAb pretreatment on the subsequent distribution of a 1 mg/kg i.v. (ϩ)-METH dose. Based on our previous studies with an anti-phencyclidine mAb, we hypothesized that the highly specific, high-affinity anti-(ϩ)-METH mAb would have dramatic but differential effects on (ϩ)-METH serum and tissue distribution. We think our hypothesis was confirmed; however, some of the changes in (ϩ)-METH disposition cannot be explained based solely on pharmacokinetic principles, and may be due to the mAb itself.
Although the anti-(ϩ)-METH mAb dramatically decreased brain AUC 0 4.5 h , it did not significantly decrease brain (ϩ)-METH concentrations at the earliest time points (i.e., during the first 15 min; Fig. 3) . Thus, even though the mAb has a high affinity for (ϩ)-METH, it did not block the initial distribution of (ϩ)-METH into the brain. This suggests that the association rate of (ϩ)-METH with the anti-(ϩ)-METH-mAb was not fast enough to prevent this early penetration of (ϩ)-METH into the brain. The serum protein binding data support this hypothesis (Fig. 2) . Maximum serum protein binding was not reached until 15 min after (ϩ)-METH administration, and at this time point, (ϩ)-METH brain concentrations began to decrease significantly compared with controls. Although the capacity and K D value of the mAb are very important considerations for these studies, the K D value is derived under equilibrium conditions in buffered solutions. It is important to note that the experiments in the current study were not conducted at equilibrium. In reality, drug concentrations are rapidly changing due to mAb binding, along with drug distribution, metabolism, and elimination. Thus, the in vivo association and dissociation with the mAb may be different from those predicted by in vitro studies.
Pretreatment with mAb resulted in Ͼ95% binding of (ϩ)-METH in the serum after the first 15 min, which resulted in a 6600% increase in serum total (ϩ)-METH concentrations. However, the estimated free concentration of (ϩ)-METH in the serum did not appear to be greatly affected by mAb. Nevertheless, (ϩ)-METH tissue concentrations and AUC 0 4.5 h were significantly decreased in some tissues (Table 1; Figs. 3 and 4) . At this time, we do not have an adequate explanation for these findings; however, we have observed analogous results with phencyclidine and anti-phencyclidine Fab and mAb Proksch et al., 2000) . Clearly, further studies are needed to understand these findings.
Because (ϩ)-METH bound to anti-(ϩ)-METH mAb takes on the pharmacokinetic profile of the mAb, the half-life of (ϩ)-METH appeared to increase in the mAb-pretreated rats. Thus, the 0-to 4.5-h time period measured is only a fraction of the total AUC (0 -infinity) in the mAb-treated rats. Therefore, it is possible that as free (ϩ)-METH re-equilibrates in the body, concentrations of (ϩ)-METH in the tissues may rebound over time. However, based on our behavioral studies, which were conducted for 8 h (Byrnes-Blake et al. estimated free (ϩ)-METH serum AUC 0 4.5 h (values in parentheses in Table 1 ) also suggest differential effects in the tissues. We believe these differences are partly a function of the tissue-specific distribution properties of (ϩ)-METH under control conditions (without mAb). For example, in control animals, maximum tissue concentrations of (ϩ)-METH were achieved at the earliest (0.5-min) time point in the brain and kidney. However, in testis and spleen, maximum (ϩ)-METH concentrations were not reached until the 38-min time point. This suggests that (ϩ)-METH distribution in brain and kidney is rapid and blood flow-limited, and that testis and spleen (ϩ)-METH are slower to equilibrate and appear to have membrane-limited distribution. Thus, it appears that organs in which (ϩ)-METH distribution is limited only by blood flow "benefit" more from the anti-(ϩ)-METH mAb effects than organs in which (ϩ)-METH distribution is restricted by tissue membrane penetration. In line with this idea, differences in blood clearance by organs due to changes in protein binding may also contribute to these effects. In control animals, protein binding is negligible, but in mAb-treated rats, it is a significant factor. Thus, brain and kidney clearance changes from a nonrestrictive type to a restrictive type of clearance in the presence of the mAb, which leads to reduced organ concentrations. Regardless of the mechanism, the anti-(ϩ)-METH mAb is effective at reducing (ϩ)-METH concentrations in target tissues and at reversing (ϩ)-METH behavioral effects in a rat (ϩ)-METH overdose model (Byrnes-Blake et al., 2003) .
These differential effects of the mAb on tissue (ϩ)-METH concentrations and AUC 0 4.5 h may also involve differential tissue penetration of the mAb itself. Physiology-based pharmacokinetic models of antibody distribution have shown differences in antibody tissue levels (Baxter et al., 1994 (Baxter et al., , 1995 . Interestingly, another study of antibody distribution showed that antibody penetration into the brain is lowest compared with other tissues (Hong et al., 1999) , and others have described receptor-mediated efflux of antibody molecules from brain to blood (Zhang and Pardridge, 2001; Schlachetzki et al., 2002) . These differences in tissue antibody distribution may also contribute to the observed differences of the anti-METH mAb on (ϩ)-METH tissue concentrations. Regardless of the mechanism, our studies are in agreement with previous studies that show differential effects of anti-drug mAb on tissue drug distribution (Pentel et al., 1991; Ragusi et al., 1998; Proksch et al., 2000) .
In contrast to other tissues from mAb-treated rats in which there were decreases or no significant change, the liver (ϩ)-METH AUC Kosugi et al., 1992) , the increase in (ϩ)-METH liver concentration could in part be due to uptake of (ϩ)-METH-mAb complex. The uptake of this bound complex (and subsequent transfer to lysosomes) may prevent or delay metabolism of (ϩ)-METH, resulting in increased liver (ϩ)-METH concentrations. From the pharmacokinetic analysis we know that pretreatment with anti-(ϩ)-METH mAb reduced the (ϩ)-METH Vd from 5.5 l/kg to 0.23 l/kg; thus, the mAb appears to limit the apparent space in which (ϩ)-METH can distribute. Consequently, another factor that could contribute to the increased liver concentration is the decreased Vd of (ϩ)-METH in the presence of mAb, if the liver is part of the central compartment. Other investigators have also reported increased liver concentrations of drugs in rats following treatment with anti-drug mouse mAbs (Pentel et al., 1991; Ragusi et al., 1998) .
Due to the mAb's limited cross-reactivity with (ϩ)-AMP in vitro, it was expected to have little effect on this metabolite's distribution in vivo. Although the minor changes in (ϩ)-AMP serum concentration in the mAb-treated rats were significant, they were not dramatic, and the serum (ϩ)-AMP AUC 0 4.5 h did not change ( Fig. 1; Table 1 ). Since the free (ϩ)-METH serum concentration was similar in control and
FIG. 4. Tissue concentration-time profiles for (ϩ)-METH and (ϩ)-AMP with (F) and without (E) anti-(ϩ)-METH mAb pretreatment.
Rats were treated with vehicle or anti-(ϩ)-METH mAb. Seventeen hours later, they received a 1 mg/kg (ϩ)-METH i.v. dose. Rats were sacrificed at various time points (n ϭ 3 per time point) after (ϩ)-METH administration. Brain (ϩ)-METH and (ϩ)-AMP concentrations were determined by HPLC separation followed by liquid scintillation spectrometry. Values represent mean Ϯ S.D. Asterisks indicate points significantly different from control values (p Ͻ 0.05).
TABLE 2
Changes in tissue (ϩ)-AMP to (ϩ)-METH AUC molar ratios in control and
mAb-treated rats. mAb-treated rats, it seems reasonable that the (ϩ)-AMP serum concentration was not dramatically different. Indeed, the ratio of serum (ϩ)-AMP to free (ϩ)-METH did not change in mAb-treated rats compared with control rats. However, there were significant decreases in (ϩ)-AMP concentration and AUC 0 4.5 h in almost all of the tissues examined ( Fig. 4; Table 1 ). Based on our pharmacokinetic analysis, the apparent Vd for (ϩ)-AMP decreased by 50% in the mAb-treated rats compared with control rats. This decrease in (ϩ)-AMP Vd correlates well with the observed ϳ50% decrease in (ϩ)-AMP AUC 0 4.5 h observed in the tissues. Thus, it appears that changes in (ϩ)-METH disposition limit the formation of (ϩ)-AMP. However, the changes in (ϩ)-METH and (ϩ)-AMP concentrations are difficult to reconcile, and further studies will be necessary to elucidate the mechanisms for these effects.
In conclusion, these studies demonstrate that pretreatment with an anti-(ϩ)-METH mAb can dramatically alter the disposition (both distribution and metabolism) of (ϩ)-METH through high-affinity binding in the serum. The alterations in (ϩ)-METH disposition resulted in significant changes in the pharmacokinetics of a pharmacologically active (ϩ)-METH metabolite, (ϩ)-AMP. However, some of the effects could not be explained with pharmacokinetic principles; thus, further studies are necessary to address these issues. The effects of the mAb appeared to be tissue-specific; i.e., more dramatic reductions in (ϩ)-METH concentrations were observed in rapidly equilibrating tissues, such as the brain. Although the anti-(ϩ)-METH mAb significantly decreased brain concentrations and AUC 0 4.5 h , (ϩ)-METH did not appear to associate with the mAb rapidly enough to prevent the initial distribution of (ϩ)-METH into the brain. Thus, this mAb may not be entirely effective in decreasing the initial (ϩ)-METH effects. Nevertheless, the overall decreases in brain concentrations suggest that at the correct dose, the mAb could provide reductions in at least some of the neurotoxic effects of (ϩ)-METH, such as adverse behavioral effects.
